Journal of Clinical Endocrinology & Metabolism最新文献

{"title":"Potential mechanism associated with post-heart transplantation diabetes mellitus in Chinese patients.","authors":"Xiao Huang, Qiling Xu, Linhua Chen, Li Liu, Ying Zhou, Hong Zhou, Yu Zhang","doi":"10.1210/clinem/dgaf071","DOIUrl":"https://doi.org/10.1210/clinem/dgaf071","url":null,"abstract":"<p><strong>Background: </strong>Post-transplantation diabetes mellitus (PTDM) is a common metabolic complication following heart transplantation, which not only leads to elevated microvascular morbidity, but also seriously affects graft function and recipient survival. However, the specific metabolites and underlying mechanisms are not yet fully understood.</p><p><strong>Methods: </strong>A total of 106 adult heart transplant recipients (56 PTDM and 50 non-PTDM) who followed for more than one year were enrolled in the study. The untargeted metabolomics was performed by ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). The demographic, clinical data and drug information were collected at the time of sample collection.</p><p><strong>Results: </strong>PTDM patients were older (p=0.003), with higher BMI (p=0.010), higher triglyceride levels (TG, p=0.007), and a higher prevalence of hypertension (p=0.001) than non-PTDM. A total of 1174 metabolites were detected, of which 99 metabolites showed significantly differentially abundant (VIP>1, p<0.05, FC>1.5 or <0.67). KEGG functional enrichment analysis showed these differently expressed metabolites could be further enriched in ABC transporter, carbon metabolism, retrograde endocannabinoid signaling, phospholipase D signaling pathway. Compared with non-PTDM group, glutamate, diacylglycerol (DAG) and D-sorbitol were significantly changed in PTDM through metabolomics.</p><p><strong>Conclusions: </strong>These findings may provide a novel understanding of the pathological mechanism of PTDM and could be utilized to predict the development and progression of PTDM.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143076194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TP53 Alterations Associate with Poor Response to Lenvatinib in Patients with Advanced Thyroid Cancer.","authors":"Valentina Cirello, Carla Colombo, Delfina Tosi, Alessandro Manzo, Maria Orietta Borghi, Umberto Gianelli, Giacomo Gazzano, Stefano Ferrero, Gianlorenzo Dionigi, Luca Persani, Laura Fugazzola","doi":"10.1210/clinem/dgaf056","DOIUrl":"https://doi.org/10.1210/clinem/dgaf056","url":null,"abstract":"<p><strong>Context: </strong>No data are available about the possible association of TP53 mutations and the response to multikinase inhibitors (MKIs) in thyroid cancer (TC).</p><p><strong>Objective: </strong>We evaluated the impact of TP53 mutations on the response to lenvatinib (LEN) in advanced TCs and in in vitro models.</p><p><strong>Patients and interventions: </strong>We investigated the molecular profile, including TP53 mutations, of 30 tumor tissues from patients treated with LEN, and tested p53 status by immunohistochemistry. These data were compared with clinical-pathological features, and tumor response to LEN. The response to LEN was also evaluated in TP53-defective and TP53-proficient TC cell lines.</p><p><strong>Results: </strong>TP53 mutations significantly correlated with a poor response to LEN (p=0.005). TP53 mutated patients had a shorter progression-free survival (PFS) (p<0.0001) and overall survival (OS) rates (p=0.0007). Accordingly, patients harbouring altered nuclear p53 protein expression had shorter PFS and OS (p=0.0001 and p=0.0056, respectively). These data were confirmed in a validation cohort. In accordance with clinical data, TC cell lines with p53 alterations had low or null sensitivity, while those TP53 wild type showed different degrees of sensitivity, primarily due to the increased number of tumor cells in G1 phase, consistent with the cytostatic effect of LEN.</p><p><strong>Conclusions: </strong>We show for the first time in advanced TC that the presence of TP53 alterations is a predictor of poor response to LEN treatment and associates to worse PFS and OS rates. The evaluation of TP53 mutations/p53 expression might be included into the patient/tumor characterization to be done before starting an MKI treatment.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143076195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor from Lin et al.: \"Testosterone Treatment, Weight Loss, and Health-related Quality of Life and Psychosocial Function in Men: A 2-year Randomized Controlled Trial\".","authors":"Kuo-Jen Lin, I-Hung Shao, Yu-Hsiang Lin","doi":"10.1210/clinem/dgaf066","DOIUrl":"https://doi.org/10.1210/clinem/dgaf066","url":null,"abstract":"","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Response to Letter to the Editor from Lin et al.: \"Testosterone Treatment, Weight Loss, and Health-related Quality of Life and Psychosocial Function in Men: A 2-year Randomized Controlled Trial\".","authors":"Mathis Grossmann, Kristy P Robledo, Mark Daniel, David J Handelsman, Warrick J Inder, Bronwyn G A Stuckey, Bu B Yeap, Mark Ng Tang Fui, Karen Bracken, Carolyn A Allan, David Jesudason, Jeffrey D Zajac, Gary A Wittert","doi":"10.1210/clinem/dgaf067","DOIUrl":"https://doi.org/10.1210/clinem/dgaf067","url":null,"abstract":"","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revolutionizing OGTT: Unlocking the Real-time Insights and Expanded Data of Continuous Glucose Monitoring (CGM).","authors":"Sujatha Seetharaman, Laya Ekhlaspour","doi":"10.1210/clinem/dgaf068","DOIUrl":"https://doi.org/10.1210/clinem/dgaf068","url":null,"abstract":"","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Houston We Have a Problem….\": Raising the Quality and Authenticity of Manuscripts Submitted to JCEM.","authors":"Paul M Stewart","doi":"10.1210/clinem/dgaf036","DOIUrl":"https://doi.org/10.1210/clinem/dgaf036","url":null,"abstract":"","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone Health and Linear Growth in Children with Familial Hypoparathyroidism Treated with Human Parathyroid Hormone 1-34.","authors":"Karen K Winer, Babette S Zemel, Andrea Kelly, James C Reynolds, Joseph Pechacek, Taura Webb, Didier Hans, Michail S Lionakis, Heidi J Kalkwarf","doi":"10.1210/clinem/dgaf065","DOIUrl":"https://doi.org/10.1210/clinem/dgaf065","url":null,"abstract":"<p><strong>Context: </strong>Our study explores the impact of human PTH 1-34 injections (PTH therapy) on growth, areal bone mineral density (BMD), and bone quality (measured by trabecular bone score, TBS) in hypoparathyroidism due to autoimmune polyendocrine syndrome type 1 (APS-1) or an activating variant of the calcium sensing receptor (CaR).</p><p><strong>Objective: </strong>To assess associations of 1) age and PTH therapy duration with age-standardized Z-scores for height (HAZ), BMD (BMD-Z), and TBS (TBS-Z) in CaR or APS-1, and 2) APS-1 disease severity with BMD-Z and TBS-Z.</p><p><strong>Methods: </strong>This secondary analysis pooled linear growth and lumbar spine (LS) DXA data from studies of hypoparathyroidism with mean baseline age of 13.7±5.5y. Comparing the two diagnostic etiologies (18 APS-1 and 9 CaR), we examined the impact of age and PTH duration on HAZ, LS-BMD-Z, and LS-TBS-Z using longitudinal mixed-effects modeling.</p><p><strong>Results: </strong>During PTH therapy, mean HAZ remained below zero in the APS-1 group at all ages, whereas HAZ increased in the CaR group (age by group interaction p<0.0001). Mean LS-BMD-Z were normal (BMD-Z:0±1) for both groups. Mean LS-TBS-Z were near or above zero and differed by group; CaR showed an upward trajectory according to time on PTH whereas the APS-1 group maintained a LS-TBS-Z of approximately 0 (time by group interaction p=0.02). The APS-1 group with greater disease severity (≥7 manifestations) had lower LS-BMD-Z and LS-TBS-Z compared to the less severe APS-1 or CaR groups.</p><p><strong>Conclusion: </strong>Our study highlights distinct growth and BMD patterns in APS-1 and CaR and underscores the need for careful monitoring and tailored treatment strategies to optimize growth and bone health.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term Thyroid Outcomes After COVID-19 Vaccination: A Cohort Study of 2,333,496 Patients from the TriNetX Network.","authors":"Kai-Lun Cheng, Wei-Shin Yu, Yu-Hsun Wang, Gema Hernández Ibarburu, Hsiang-Lin Lee, James Cheng-Chung Wei","doi":"10.1210/clinem/dgaf064","DOIUrl":"https://doi.org/10.1210/clinem/dgaf064","url":null,"abstract":"<p><strong>Context: </strong>Reports on long-term thyroid dysfunction following COVID-19 vaccination are limited. Understanding the risk of subacute thyroiditis, hyperthyroidism, and hypothyroidism in vaccinated individuals is crucial for post-vaccination monitoring.</p><p><strong>Objective: </strong>This study evaluated the risk of thyroid dysfunction in COVID-19 vaccinated individuals compared to unvaccinated individuals using a large cohort.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study from January 1, 2022, to December 31, 2023, using the TriNetX database, including 1,166,748 vaccinated and 1,166,748 unvaccinated individuals. Propensity score matching was used to balance baseline characteristics. The primary outcomes were new diagnoses of subacute thyroiditis, hyperthyroidism, and hypothyroidism.</p><p><strong>Results: </strong>The risk of subacute thyroiditis remained unchanged (95% confidence intervals [CIs] included 1). A significant reduction in hyperthyroidism risk was observed from 3 to 9 months post-vaccination (hazard ratios [HRs]: 0.65-0.89, all 95% CIs below 1), but this trend was not significant at 12 months (HR: 0.99, 95% CI: 0.92-1.06). In contrast, the risk of hypothyroidism significantly increased from 6 to 12 months post-vaccination (HR: 1.14-1.30, all 95% CIs above 1). Among mRNA vaccine recipients, the risk of both hyperthyroidism and hypothyroidism was significantly elevated at 12 months (HR: 1.16-2.13).</p><p><strong>Conclusion: </strong>COVID-19 vaccination was associated with a reduced risk of hyperthyroidism and an increased risk of hypothyroidism, highlighting the need for ongoing thyroid function monitoring.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic Profiles of Pregnancy with Polycystic Ovary Syndrome: Insights into Maternal-Fetal Metabolic Communication.","authors":"Huisheng Ge, Dongni Huang, Lunbo Tan, Dan Luo, Liu Zhou, Hong Liu, Yilan Zhang, Dandan Liu, Xixi Wu, Lulu Wang, Liling Xiong, Yang Yang, Ting-Li Han, Chengjin He, Hongbo Qi","doi":"10.1210/clinem/dgaf057","DOIUrl":"https://doi.org/10.1210/clinem/dgaf057","url":null,"abstract":"<p><strong>Context: </strong>PCOS pregnancies are linked to metabolic disorders affecting maternal and fetal outcomes, with maternal metabolites differing from those in normal pregnancies.</p><p><strong>Objective: </strong>To investigate the metabolic communication at the maternal-fetal interface in PCOS pregnancies.</p><p><strong>Design: </strong>Placenta and umbilical cord serum were analyzed using gas chromatography-mass spectrometry. In-depth analysis was performed with clinical characteristics.</p><p><strong>Setting: </strong>Placenta and umbilical cord serum were analyzed using gas chromatography-mass spectrometry, alongside clinical characteristics.</p><p><strong>Participants: </strong>45 uncomplicated PCOS pregnancies and 50 normal pregnancies.</p><p><strong>Intervention(s): </strong>None.</p><p><strong>Main outcome measure(s): </strong>The metabolic characteristics at the maternal-fetal interface in PCOS pregnancies and the underlying mechanisms.</p><p><strong>Results: </strong>A total of 79 metabolites in the placenta and 25 in umbilical cord serum showed significant differences between polycystic ovary syndrome (PCOS) and normal pregnancies. The 10 most significant placental metabolites were identified through receiver operating characteristic (ROC) analysis, 9 of which correlated significantly with maternal serum testosterone levels. Lasso regression analysis identified 4 key placental metabolite combinations: gamma-aminobutyric acid, proline, glycine, and isoleucine, achieving an area under the curve (AUC) of 93.24%. In umbilical cord serum, 6 metabolites differed significantly between PCOS and normal pregnancies, with the highest AUC reaching 76.07%, and 5 of these metabolites showed significant correlations with maternal serum testosterone levels. Nine differential metabolites were shared between the placenta and umbilical cord serum, which also shared metabolic pathways, including ABC transporters and aminoacyl-tRNA biosynthesis, potentially influencing maternal-fetal interactions.</p><p><strong>Conclusion: </strong>This study identifies the metabolomic profile and key pathways in maternal-fetal communication during PCOS pregnancies.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiofrequency ablation for thyroid nodules (RATED study) - analysis of a learning curve and predictors of success.","authors":"Manon M D van der Meeren, Tim Boers, Pim de Graaf, Katya M Duvivier, Koen M A Dreijerink, Laura N Deden, Peter Veendrick, Paul Cernohorsky, Frank B M Joosten, Angelique B M C Savelberg, Sicco J Braak, Sean H P P Roerink, Michel Versluis, Srirang Manohar, Wim J G Oyen","doi":"10.1210/clinem/dgaf058","DOIUrl":"https://doi.org/10.1210/clinem/dgaf058","url":null,"abstract":"<p><strong>Context: </strong>Radiofrequency ablation (RFA) is used as treatment for symptomatic thyroid nodules. Factors influencing the volume reduction ratio (VRR) at 12 months are not yet fully understood.</p><p><strong>Objective: </strong>The primary objective was evaluating the VRR at 12 months after RFA. Secondary objectives were the assessment of a learning curve and factors influencing the VRR at 12 months.</p><p><strong>Design: </strong>A retrospective observational cohort study.</p><p><strong>Setting: </strong>Three Dutch referral hospitals.</p><p><strong>Patients and intervention: </strong>Patients who underwent RFA for symptomatic thyroid nodules with available ultrasound follow-up.</p><p><strong>Main outcome measures: </strong>Ultrasound based VRR at 12 months and chronologically numbered RFA procedures. All patients' baseline, treatment, and early follow-up factors were assessed for correlation with VRR at 12 months.</p><p><strong>Results: </strong>A total of 337 patients with 356 nodules were included in the learning curve analysis. VRR at 12 months increases for the first 20 treatments per center and stabilizes thereafter, indicating a plateau phase after a learning curve. These initial cases were removed from further analysis. In the remaining 299 nodules, median VRR at 3, 6 and 12 months was 57.1, 65.6 and 70.8%. Baseline nodule volume negatively correlated with VRR at 12 months but VRR was high for every volume category. Energy delivered per volume did not correlate to VRR.</p><p><strong>Conclusions: </strong>In RFA for thyroid nodules a stable treatment efficacy is achieved after 20 treatments, with a median VRR of 70.8%. Baseline nodule volume, energy delivered and prolonged follow-up 6 months after treatment may not be clinically relevant to predict treatment success.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}